key: cord-0929816-8mnfx8wo authors: Fu, Leiwen; Wang, Bingyi; Yuan, Tanwei; Chen, Xiaoting; Ao, Yunlong; Fitzpatrick, Tom; Li, Peiyang; Zhou, Yiguo; Lin, Yifan; Duan, Qibin; Luo, Ganfeng; Fan, Song; Lu, Yong; Feng, Anping; Zhan, Yuewei; Liang, Bowen; Cai, Weiping; Zhang, Lin; Du, Xiangjun; Shu, Yuelong; Li, Linghua; Zou, Huachun title: Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis date: 2020-04-10 journal: J Infect DOI: 10.1016/j.jinf.2020.03.041 sha: b0b42d2e142d27e329cb75ccd01e108c53696e77 doc_id: 929816 cord_uid: 8mnfx8wo OBJECTIVE: To better inform efforts to treat and control the current outbreak with a comprehensive characterization of COVID-19. METHODS: We searched PubMed, EMBASE, Web of Science, and CNKI (Chinese Database) for studies published as of March 2, 2020, and we searched references of identified articles. Studies were reviewed for methodological quality. A random-effects model was used to pool results. Heterogeneity was assessed using I(2). Publication bias was assessed using Egger's test. RESULTS: 43 studies involving 3600 patients were included. Among COVID-19 patients, fever (83.3% [95% CI 78.4–87.7]), cough (60.3% [54.2–66.3]), and fatigue (38.0% [29.8–46.5]) were the most common clinical symptoms. The most common laboratory abnormalities were elevated C-reactive protein (68.6% [58.2–78.2]), decreased lymphocyte count (57.4% [44.8–69.5]) and increased lactate dehydrogenase (51.6% [31.4–71.6]). Ground-glass opacities (80.0% [67.3–90.4]) and bilateral pneumonia (73.2% [63.4–82.1]) were the most frequently reported findings on computed tomography. The overall estimated proportion of severe cases and case-fatality rate (CFR) was 25.6% (17.4–34.9) and 3.6% (1.1–7.2), respectively. CFR and laboratory abnormalities were higher in severe cases, patients from Wuhan, and older patients, but CFR did not differ by gender. CONCLUSIONS: The majority of COVID-19 cases are symptomatic with a moderate CFR. Patients living in Wuhan, older patients, and those with medical comorbidities tend to have more severe clinical symptoms and higher CFR. and that fever, sore throat, and muscle soreness or fatigue were the most common symptoms. In that review the incidence of abnormal chest computer tomography (CT) was 96.6%. However, this article analysed results from only ten studies, including one Chinese Center for Disease Control and Prevention (CDC) report that provides epidemiological data only, and four preprint articles (one was already withdrawn) that are not peer reviewed. Although the number of COVID-19 cases continues to grow worldwide, little attention has been paid to summarizing the clinical signs, risk factors, laboratory and chest CT findings, complications, and treatments of COVID-19. We performed a systematic review and meta-analysis to provide a comprehensive characterization of COVID-19 to better inform efforts to treat and control the current outbreak. Our systematic review and meta-analysis was undertaken according to PRISMA We used the quality assessment tool for case series studies published by the National Institutes of Health (NIH) to assess the methodological quality of included studies. [53] We scored 0 or 1 point for each item according to the criteria and added scores for all items to generate an overall quality score that ranged from 0 to 9. Based on the overall score, we classified studies as low (≥7), moderate (5-6), or high risk of bias (≤4). Any disagreement was resolved through discussion by all investigators. We performed data analyses using meta packages in R (version 3.6.0). Random-effects meta-analysis was used to calculate pooled estimated prevalence with 95% confidence intervals of clinical symptoms, laboratory findings, chest CT findings, complications, treatment, and fatality of COVID-19 patients. [54] To minimize the impact of studies with extremely small or extremely large prevalence estimates on overall estimates, Freeman-Tukey double arcsine transformation was used to stabilize the variance of specific prevalence rates before using random-effects meta-analysis models to pool data. [54] We assessed heterogeneity between studies using I 2 , with values of 25%, 50%, and 75% representing low, moderate, and high heterogeneity, respectively. [55] If substantial heterogeneity (I 2 >75%) was detected, we further explored the possible source of heterogeneity through subgroup analysis and used the following grouping variables: age, sex, region, and underlying medical comorbidities. We also performed subgroup analyses to explore whether the prevalence of outcomes differed by these subgroups. If a meta-analysis included more than three studies, publication bias was assessed by Egger's test. [56] Our search produced 2247 publications. Of these, 1648 were unique records, from which 1434 records were excluded after screening their titles and abstracts (figure 1). We assessed the eligibility of 214 full-text papers, of which 99 did not report original data, 47 did not report clinical features of COVID-19 (e.g., epidemiological characteristics, mathematical models, virus structure), six did not include clear diagnostic criteria, 17 had a sample size smaller than four, two were conducted outside mainland China, and one focused on patients aged less than one year. After excluding these studies, 43 eligible studies with 3600 patients were included. Among included studies, one study only reported data on critically ill patients and was excluded from the overall meta-analysis but was included in the meta-analysis restricted to patients with severe illness.[1, 5, 6, 11-50] to 72 years (median 41 years; 43 studies). The proportion of male patients ranged from 29.0% to 77.0% (median 56.5%; 42 studies). The proportion of patients who had ever traveled to or were resident of Hubei Province varied from 28.5% to 100.0% (median 91.0%; 36 studies). The number of familyclusters ranged from 1 to 5 (10 studies). The proportion of patients who were current smokers ranged from 0.0% to 18.0% (median 7.2%; 9 studies), and health workers ranged from 0.0% to 29.0% (median 4.0%; 5 studies). The proportion of patients with hypertension ranged from 0.0% to 48.0% (median 16.0%;27 studies), diabetes ranged from 0.0% to 50.0% (median 10.1%; 26 studies), cancer ranged from 0.0% to 17.0% (median 1.0%; 15 studies), chronic respiratory/lung diseases ranged from 0.0% to 17.0% (median 2.0%; 16 studies), having any coexisting medical comorbidity ranged from 12.0% to 67.0%. The proportion of patients diagnosed with severe COVID-19 varied from 0.0% to 100.0% (median 26.5%; 21 studies), and the most commonly In subgroup analysis (supplementary table2-5), studies from Wuhan had significantly higher prevalence of death, fever, fatigue, headache, elevated leukocyte count, and elevated lactate dehydrogenase, and elevated aspartate aminotransferase compared to patients from other cities (all p<0.05). Similarly, the prevalence of death, ARDS, headache, increased leukocyte count, and increased lactate dehydrogenase were significantly higher in studies in which the proportion of older patients was larger (all p<0.05), and the prevalence of diarrhea, and elevated lactate dehydrogenase were significantly higher in studies in which the proportion of patients with any coexisting medical condition was larger (all p<0.05). The prevalence of fatigue, myalgia, decreased leucocyte count were significantly higher in studies in which the proportion of male patients was smaller, whereas the reverse was true for the prevalence of elevated aspartate aminotransferase and lactate dehydrogenase (all p<0.05), though fatality did not differ by gender. A total of eight studies reported separate results for severe cases and nonsevere cases. Overall, the existence of clinical symptoms, abnormalities in laboratory and chest CT findings, and complications were higher among patients with severe illness compared to patients without severe illness (table2), however these differences were not statistically significant due to limited sample size and statistical power (data not shown). Publication bias was found in the following subgroup outcomes: fever, myalgia, diarrhea, rhinorrhea, hemoptysis, decreased leucocytes, lymphopenia, increased creatine, creatine kinase, and procalcitonin, bilateral pneumonia, solid nodules, antiviral therapy, and immunoglobulin therapy (figure 2-4, all p<0.005 by Egger test). Substantial heterogeneity was present within most subgroups (table 2 and The most frequently reported laboratory abnormalities were reduced lymphocyte count, elevated C-reactive protein, and elevated lactate dehydrogenase, all of which are generally consistent with previous reports of patients with COVID-19. [11, 19, 24] However, all these laboratory markers are very non-specific, making their clinical utility limited. When evaluating suspected cases, physicians cannot rely on these laboratory abnormalities to exclude or confirm the diagnosis of COVID-19. These abnormalities are similar to those previously observed in patients with SARS and MERS. [57] [58] [59] Previous research suggests these abnormalities may be related to the cytokine storm brought on by infection. [22] Recently, a study suggested that COVID-19 may primarily affect T lymphocytes, especially CD4+ T cells, resulting in significant lymphopenia as well as decreased IFN-γ production. [60] Additionally, by using a multiple linear regression model, a study showed that CD4+ T lymphocyte count may help predict the duration of viral RNA detection in patients' stools (p=0·010). [61] However, the number of cases currently reported is too small to draw firm conclusions, and further studies are required. The most frequently reported finding on CT imaging was ground-glass opacities, particularly bilateral opacities impacting three or more lobes. These results are also consistent with previous studies, [21] and are also frequently identified in MERS and SARS. [57] [58] [59] In this systematic review and meta-analysis, we found a CFR of 3.6%, which is closer to the estimate (2.3%) in a report by the Chinese Center for Disease In our analysis, the proportion of severe cases (25.6%) was close to the estimate in the China CDC report (18.5%). [10] This is consistent with previous studies that patients from Wuhan had significantly higher prevalence of death, fever, elevated leucocyte count, and elevated aspartate aminotransferase compared with patients from other cities in China (all p<0.05).[1, 14, 19 Our study did not find significant differences between men and women in terms of CFR and proportion of severe cases. This finding is similar to a previous study in which there was no difference in the proportion of men and women admitted to the intensive care unit (ICU) for treatment of COVID-19. [6] However, this differs from another study which found that men are more susceptible to COVID-19 than women, [63] as well as a recent publication reporting that seven of nine infant patients were female. [64] There is no clear explanation as to why men and women would be at different risk of infection, however some have proposed genetic mechanisms or sex-specific effects. [65] Whether there are differences in risk of infection between men and women requires further research. We found the prognosis was worse among severe cases compared to nonsevere cases, however these differences were not statistically significant, which is likely due to insufficient sample size. In our research, there was no significant difference in the degree of lymphocyte decline between severe cases and non-severe cases. This conclusion can be supported by this research that the expression level of lymphocyte counts has no significant correlation with the severity of the disease. [22] However, some studies showed that lymphocytopenia is a prominent feature of severe cases. [45] At present, it is unclear whether lymphocyte count is related to severity of disease. Further investigation is needed to establish whether lymphocytosis or lymphopenia can help predict mortality in COVID-19 patients. [62] We found many patients were treated with antiviral and antibiotic therapy. Authors misuse fundamental terms. They mistake incidence for prevalence and odds ratio for proportion. They demonstrate the proportion of severe cases is 88% and case fatality rate is 42% in figures, which are misleading. PRISMA guidelines and test for heterogeneity were not mentioned. Authors state in Methods that "Only available data from published articles were collected. Data from unpublished papers were not included." However 4 out of 10 references were from Medrxiv, a platform that publishes non-peer reviewed reports. These reports, as it clearly states on Medrxiv's website, should not be relied on to guide clinical practice or health-related behavior and should not be reported as established information. One reference providing 4021 cases was already withdrawn from publication. [66] It is inappropriate to include the China CDC report providing epidemiological characteristics of 44672 cases of COVID-19 (as of February 11, 2020) in a meta-analysis of its clinical characteristics. [10] This report, based on national surveillance data, provides epidemiological data only, including spatiotemporal distribution. Albeit this report includes a large sample, data on clinical symptoms that are not systematically reported, may not be reliable. For example, 53% did not report if they have co-morbidity or not. 9 out 10 studies included in the meta-analysis were published/submitted before February 11, 2020 so cases in these 9 studies must have already been included in the China CDC report. It is inappropriate to count an individual twice. After excluding the China CDC report and the four preprint articles, only 369 patients would be reportable in that review. Authors did not list specific imaging performance in abnormal imaging, nor did they list pulmonary fibrosis and its incidence. However in Discussion they use two lengthy paragraphs to explain the content of pulmonary fibrosis, which may cause readers to mistakenly believe that the imaging abnormality is pulmonary fibrosis. Author failed to report any clinical laboratory findings and treatments of COVID-19 which are essential to a thorough understanding of clinical characteristics. They also failed to report the diagnostic criteria for abnormal chest CT detection and severe cases. Our systematic review and meta-analysis has limitations. First, we found substantial heterogeneity between studies and significant publication bias among several subgroups. Second, this study performs an analysis during an ongoing outbreak. Many regions affected by COVID-19 haven not yet published clinical datasets, which may skew the results of this analysis. All these datasets are retrospective, which prevents us from exploring risk factors. Additionally, our meta-analysis focused on Chinese people, not those infected in other countries, so geographical and ethnic differences were not excluded. Finally, the meta-analysis was performed by comparing entire datasets against one another, therefore there was no way to analyse data on the level of individual patients. This review provides a comprehensive characterization of clinical features among COVID-19 patients. Patients living in Wuhan, older patients, and those with medical comorbidities tend to have more severe clinical symptoms and higher fatality. Better therapeutics are crucial for the treatment of severe cases. Our comprehensive characterization of COVID-19 will inform healthcare providers and public health policy makers in their efforts to treat and control the current outbreak. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group Meta-analysis of prevalence Measuring inconsistency in meta-analyses Bias in meta-analysis detected by a simple, graphical test Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study Hospital outbreak of Middle East respiratory syndrome coronavirus Clinical and immunologic features in severe and moderate forms of Coronavirus Disease COVID-19 in a Designated Infectious Diseases HospitalOutside Hubei Province Clinical Characteristics of 2019 Novel Infected Coronavirus Pneumonia：A Systemic Review and Metaanalysis Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China The X chromosome and sexspecific effects in infectious disease susceptibility Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China